摘要
目的探讨尿激酶型纤溶酶原激活剂(urokinase type plasmivnogen activator,UPA)和血管内皮生长因子(vas-calia endothelial grouth factor,VEGF)在乳腺癌中的表达及与临床病理特征的关系。方法利用SP免疫组织化学方法检测86例乳腺癌、46例腺瘤中UPA和VEGF的表达,并分析它们之间的关系。结果 UPA和VEGF在乳腺腺瘤中阳性率分别为32.61%(15/46)和34.78%(16/46);乳腺癌中阳性率前者为58.89%(53/90),后者为56.67%(51/90),在乳腺癌中的表达明显高于腺瘤(P<0.05);在浸润型癌组的表达明显高于原位癌组(P<0.05);淋巴结转移组明显高于无转移组(P<0.05)。结论 UPA和VEGF高表达与乳腺癌发生及转移有关,而且两者呈低度正相关。检测乳腺癌UPA和VEGF对提示预后和靶向化学治疗有指导作用。
Objective To discuss the relationship between clinicopathological features and expressions of urokinase type plasmivnogen activator （UPA） and vascalia endothelial grouth factor （VEGF） in breast cancer. Methods 86 cases of breast cancer, 46 cases of adenoma were examined by immunohistochemical method for expressions of UPA and VEGF. The relationship of them was analysed. Results The positive rates of UPA and VEGF in breast adenoma were 32.61%（15/46） and 34.78% （16/46）, they were 58.89% （53/90） and 56.67% （51/90） in breast cancer. The positive rates of UPA and VEGF in breast cancer were higher than that of in adenoma （P 〈 0.05）. The expressions of them in the infiltration cancer group were positively higher than that of the carcinoma in situ group （P 〈 0.05）. The positive rates of UPA and VEGF in lymphmetastasis group were higher than that of in non-lymphmetastasis group （P 〈 0.05）. Conclusion The overexpressions of UPA and VEGF relate to occurrence and lymphmetastasis of breast cancer. There is lightly positive correlation between expressions of UPA and VEGF in breast cancer. The examination of UPA and VEGF is a guidance for target chemotherapy and to prompt the prognosis.
出处
《中国医药导报》
CAS
2012年第19期27-28,共2页
China Medical Herald
基金
河北省张家口市科技局课题(项目编号:0801021D)
关键词
乳腺癌
腺瘤
尿激酶型纤溶酶原激活剂
血管内皮生长因子
免疫组化学
Breast cancer
Adenoma
Urokinase type plasmivnogen activator
Vasculiar endothelial growth factor
Immunohistochemical
